Immunovant, Inc.

Biotechnology company · Durham, North Carolina, United States · Nasdaq: IMVT

Immunovant, Inc. is a biotechnology company headquartered in Durham, North Carolina, United States. Its shares trade on Nasdaq under the ticker IMVT. It has reported private securities offerings to the US SEC, most recently $450 million sold in a notice filed in 2025.

Profile compiled from public records. Is this your company? Request a correction or update

Immunovant at a glance

Typebiotechnology company

HeadquartersDurham, North Carolina, United States

Stock listingNasdaq: IMVT

SEC industryBiological Products, (No Diagnostic Substances)

SEC CIK1764013

What does Immunovant do?

Private fundraising reported to the SEC

1 Form D notice; the most recent reported $450 million sold (2025).

Frequently asked questions about Immunovant

Where is Immunovant headquartered?

Immunovant, Inc. is headquartered in Durham, North Carolina, United States.

What does Immunovant do?

Immunovant, Inc. is a biotechnology company. Its SEC industry classification is Biological Products, (No Diagnostic Substances).

Is Immunovant a public company?

Yes. Immunovant, Inc. trades on Nasdaq under the ticker IMVT.

Similar companies

Humacyte, Inc.Durham, North Carolina, United States
Precision Biosciences IncDurham, North Carolina, United States
Xilis, Inc.Durham, North Carolina, United States
inSoma Bio, Inc.Durham, North Carolina, United States
Atsena Therapeutics, Inc.Durham, North Carolina, United States
Scion Neurostim, Inc.Durham, North Carolina, United States
Sapere Bio, Inc.Durham, North Carolina, United States
BioAesthetics CorpDurham, North Carolina, United States

Need a CRO or CDMO for your next study?

Compare transparent quotes from research and manufacturing partners, then contract once. Free for buyers.

Compare quotes

Last updated 2026-09-25. Data licences